PZ-601 antibacterial activity against well-characterised and fresh Enterobacteriaceae isolates
Abstract number: 1733_1168
Mezzatesta M., Trovato M., Gona F., Santagati M., Campanile F., Stefani S.
Objectives: The in vitro activity of PZ-601, formerly SMP-601, an investigational broad-spectrum carbapenem antibiotic, with potent activity against multi-drug resistant Gram-positive and Gram-negative bacteria, was tested in comparison with other drugs against a group of well-characterised and fresh Enterobacteriaceae isolates.
Methods: The strains included in the study Escherichia coli, Klebsiella spp. and Enterobacter spp. were the first 70 Enterobacteriaceae consecutive non-repetitive strains collected from urine and respiratory tract specimens of inpatients and outpatients, isolated from the Policlinico of Catania (I) in a 4-month period, and 23 strains of Enterobacteriaceae previously molecularly characterised for their ESBL production (Luzzaro et al. JCM 2006; 44: 1659). All bacterial isolates were identified at the species level using standard procedures. Antibiotic susceptibility was determined by the standard broth microdilution method (MICs) following CLSI guidelines. The antibiotics used were: PZ-601, imipenem (IMI), ceftriaxone (CRO), cefepime (CPE), piperacillin/tazobactam (PIP/TAZ), levofloxacin (LEVO) and tobramycin (TOBRA). PZ-601 was freshly prepared and maintained in ice.
Results: PZ-601 was highly active against Enterobacteriaceae and ESBL-producing strains with MIC90 of 2 mg/L, comparable with that of imipenem, and superior to that of the other drugs tested. Among ESBL isolates, PZ-601 showed a variable activity against the strains possessing different enzymes, with a MIC90 value of 0.5 mg/L in SHV-containing strains, while it showed MIC90 values of 2 in strains containing CTX-M-type enzyme.
Conclusion: In this small sample, PZ-601 was highly active against Enterobacteriaceae and ESBL-producing isolates, demonstrating that this carbapenem is a potentially outstanding alternative drug in the empiric treatment of infections caused by these multiresistant microrganisms resistant to cephalosporins, protected penicillins, quinolones, and aminoglycosides.
|Session name:||European Society of Clinical Microbiology and Infectious Diseases|
|Location:||ICC, Munich, Germany|
|Back to top|